At Sobi, we’re dedicated to transforming the lives of people with rare and debilitating diseases. Our five values help guide us in our work. One of them is Care. We are who we are because of our dedication, knowledge, and passion. Care is the foundation upon which our strategy, business, and culture are built. Learn more about our vision and values. https://lnkd.in/epuze_K #Sobi #RareDiseases #Values
Om oss
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. We provide sustainable access to innovative therapies in the areas of haematology, immunology, and specialty indications. Today, we employ approximately 1,800 people across Europe, North America, the Middle East and Asia. In 2023, our revenue amounted to SEK 22.1 billion. The Sobi share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at sobi.com.
- Webbplats
-
http://www.sobi.com
Extern länk för Sobi - Swedish Orphan Biovitrum AB (publ)
- Bransch
- Tillverkning av läkemedel
- Företagsstorlek
- 1 001–5 000 anställda
- Huvudkontor
- Stockholm
- Typ
- Publikt aktiebolag
- Specialistområden
- orphan drugs, hereditary metabolic disorders, haemophilia, biopharmaceuticals, patient access, rare diseases, haematology, hematology, immunology och autoimmune
Adresser
-
Primär
Tomtebodavagen 23A, Solna
Stockholm, 112 76, SE
Anställda på Sobi - Swedish Orphan Biovitrum AB (publ)
Uppdateringar
-
We are excited to share that Sobi, in collaboration with Save One Life Foundation, has recently supported a group of individuals living with haemophilia in an inspiring journey towards the summit of Mont Blanc, the highest peak in the Alps, this July 2024. The climb was more than just a physical effort; it is our ambition that it will serve as a source of inspiration for everyone living with haemophilia to pursue their dreams and goals, no matter how big or small. A documentary on the climb is anticipated to be released in late 2024. Led by Chris Bombardier, Executive Director of Save One Life Foundation and the first person with haemophilia to conquer the Seven Summits, this climb aims to inspire others to overcome their personal challenges and live fuller lives. Haemophilia is a rare blood disorder that affects the blood’s ability to clot. This can leave people living with haemophilia at risk of bleeding from modest injuries or even spontaneously. For Sobi, the Mont Blanc endeavour and the mountain that these climbers aimed to overcome represents the potential for those living with haemophilia to unlock their own personal opportunities and reimagine their life with haemophilia. Learn more about support and resources for people with haemophilia on our Liberate Life website https://liberatelife.eu/ For more details about the climb, visit the Save One Life Foundation https://lnkd.in/ebtPAKN9 #Sobi #RareDiseases #Haemophilia #LiberateLife #ReimagineYourStory
-
-
We are excited to share our second quarter results, showcasing strong performance and significant progress in our pipeline. Our growth continued at 11% at CER and the adjusted EBITA margin was 28%. "The continued momentum was driven by growth in our strategic portfolio across all regions," says Guido Oelkers, President & CEO. We look forward to the second half of the year and building on this momentum. Our advancements highlight our dedication to improving the lives of those affected by rare and debilitating diseases. Explore the full report: https://lnkd.in/dNbVnPhi #Sobi #RareDiseases #InvestorRelations
-
Be part of our future and make a difference. Our commitment to patients knows no borders, and as we continue to expand, we are looking for passionate individuals to join us in shaping the future. Be part of our global family and make a difference for people with rare and debilitating diseases. Explore the possibilities – check out our open positions on LinkedIn or visit sobi.com. #Sobi #RareDiseases #CareerOpportunities
-
Our commitment to the global sustainable development agenda is at the core of our mission: transforming the lives of people living with rare and debilitating diseases. Our sustainability strategy is integrated into our business and focuses on two main priorities: maintaining our commitment to patients and always acting responsibly. By expanding our geographical reach, investing in the development of innovative medicines, and deepening our engagement in haematology, immunology, and specialty care, we are enhancing access to rare disease treatments for patients around the world, step by step. Learn more about our commitments to patients. https://lnkd.in/e6cSjDP4 #Sobi #RareDiseases #Sustainability
-
-
Embark on a journey where passion meets purpose! At Sobi, we are not just colleagues; we are a team driven by purpose with a shared commitment to making a meaningful difference for people living with rare and debilitating diseases. Ready to make a real impact and be part of Sobi’s journey? Explore career opportunities with Sobi now. Learn more about us on Linkedin or sobi.com. #Sobi #RareDiseases #Career
-
From brewing roots to global biopharmaceutical leadership – discover Sobi's legacy. Our history is a story of challenges overcome. From our Swedish origins, we have grown into an international biopharmaceutical leader, present in 30 countries and delivering medicines worldwide. Our rich heritage of collaborative expertise has empowered us to consistently identify and develop innovative medicines. We are dedicated to addressing significant unmet medical needs and transforming the lives of people living with rare and debilitating diseases. Explore our history and learn more about our journey. https://lnkd.in/dwcwATGv #Sobi #RareDiseases
-
We hope to see you at the #ISTH2024 congress, from 22-26 June in Bangkok, Thailand. We are looking forward to this event - the 32nd International Society on Thrombosis and Haemostasis (ISTH) congress. This year, we are proud to present new data further demonstrating our commitment to advancing haemophilia treatment standards. It is a fantastic opportunity to gather, connect, and learn from global bleeding and clotting disorders experts. Let’s work together to share our knowledge and improve care for people with haemophilia worldwide. #Sobi #RareDiseases #Haemophilia #ISTH2024 #BleedingDisorders
-
-
EHA2024 kicks off today! Join us at the European Hematology Association (EHA) hybrid congress, taking place from 13-16 June in Madrid, Spain. Under the EHA theme “Towards prevention, cure, and quality of life for all patients with blood disorders, this congress promises to be an insightful event. Sobi will have a strong presence at EHA with multiple symposia, oral presentations, and posters. Come visit us in the Sobi booth, we are looking forward to seeing you at EHA 2024. Sobi is proudly supporting the educational project ‘Factor Think Tank’, led by well-known experts in haemophilia, aimed at raising awareness about the current challenges in managing the condition. If you are a healthcare professional interested in haemophilia, don’t miss the opportunity to listen to leading experts. Tune in to the Factor Think Tank https://lnkd.in/dYvE4FdJ #Sobi #RareDiseases #BleedingDisorders #EHA2024 #Haemophilia
-
-
EULAR 2024 is just around the corner, and we are excited to attend EULAR - European Alliance of Associations for Rheumatology Congress, in Vienna, Austria, from 12-15 June. The EULAR congress will bring together leading experts to present and discuss the latest scientific breakthroughs in clinical, translational, and basic sciences. We look forward to engaging and forward-looking discussions on new advancements, all with the shared goal of improving the lives of patients worldwide. Hope to see you in Vienna! #Sobi #RareDiseases #EULAR2024
-
Anslutna sidor
Liknande sidor
Finansiering
Senaste finansieringsrunda
Lån efter börsintroduktion274 917 390,00 US$